Is prostate-specific antigen progression a surrogate for objective clinical progression in early prostate cancer?
Sub-category: Prostate Cancer Category: Genitourinary Cancer Meeting: 2004 ASCO Annual Meeting Session Type and Session Title: General Poster Session, Genitourinary Cancer Abstract No: 4652 Citation: Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 4652 Author(s): D. Newling, K. Carroll, T. Morris; AstraZeneca, Macclesfield, United Kingdom Abstract: Background: It is a common misconception that a correlation between endpoints is enough to demonstrate surrogacy. To show true surrogacy, the effect of an intervention on an intermediate endpoint relative to a control treatment needs to reliably predict the effect of the intervention on the clinical outcome of interest. Valid surrogate endpoints are needed to accelerate availability of information about new therapies for early prostate cancer where clinical progression and survival times are prolonged. The usefulness of prostate-specific antigen (PSA) progr
Related Questions
- Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed?
- Is prostate-specific antigen progression a surrogate for objective clinical progression in early prostate cancer?
- Does prostate-specific antigen velocity help in early detection prostate cancer?
